Mauna Kea and Endotherapeutics Introduce Cellvizio to Australia

Mauna Kea Technologies, in collaboration with Endotherapeutics, announced the addition of the Cellvizio system to the Australian Register of Therapeutic Goods. This inclusion marks the start of its commercial journey in Australia. The company has already confirmed its initial orders for the CellTolerance indication, targeting food intolerances.

Benoit Chardon's team led the market re-entry, aiming for broader global reach. They are focusing on regions like Europe and Latin America. Adam Srejber of Endotherapeutics expressed confidence in the technology's broad adoption across institutions in Australia. Discussions with various entities are already underway.

CEO Sacha Loiseau highlighted the model's potential replication in Turkey, Brazil, and the UAE, leveraging previous regulatory clearances. The partnership's swift success over six months underscores its promising market approach, particularly regarding Cellvizio's expansion opportunities.